Fidel Valea appointed to leadership roles in gynecologic oncology at Northwell Health

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Fidel A. Valea was appointed system chief of gynecologic oncology at Northwell Health and director of gynecologic oncology at the Northwell Health Cancer Institute. In these roles, he will see patients in New Hyde Park and Manhattan.

Valea is joining Northwell from the Virginia Tech Carilion School of Medicine, where he was chair of obstetrics and gynecology for five years. Prior to that, Valea held several leadership roles during his 12-year tenure at Duke University School of Medicine, including vice chair of education, residency program director in obstetrics and gynecology, fellowship director in gynecologic oncology, and tenured professor. 

In his role as system chief of gynecologic oncology at Northwell Health, Valea will direct gynecologic oncology programs across the health system. Key areas of responsibility include: advancing a patient-centered approach to care, overseeing performance improvement and quality assurance studies, enhancing operational efficiencies, developing educational and academic offerings for the fellowship program and other clinical staff, and expanding gynecologic oncology research efforts.

As director of gynecologic oncology at the Northwell Health Cancer Institute, Valea will direct the development of the gynecologic oncology program throughout the health system’s central region, working with Northwell’s Divi

sion of Gynecologic Oncology.

Valea recently completed his tenure as director of Gynecologic Oncology for the American Board of Obstetrics and Gynecology and served on its board. He is one of four editors of Comprehensive Gynecology. Valea’s research interests are in pre-invasive disease of the cervix, minimally invasive surgery, and evidence-based perioperative care. 

Table of Contents

YOU MAY BE INTERESTED IN

For nearly 25 years, business executive Lou Weisbach and urologist Richard J. Boxer have argued that finding the money to finance the cures for devastating diseases is not as difficult as it appears. To start finding the cures, the U.S. Department of the Treasury needs to issue some bonds—$750 billion worth. Next, you hire CEOs—one...

There is general agreement that the United States spends too much on health care, especially on pharmaceuticals.  But what we spend on drugs is not simply a function of price. If eggs double in price, people can simply cut the number of eggs they eat in half.  Simply stated, cost is the product of (price per unit times the number of units purchased). 
What did President Richard M. Nixon and Senator Edward M. Kennedy have in common? They each played a pivotal role in the passage of the National Cancer Act signed by Nixon on Dec. 23, 1971. The NCA established the National Cancer Program authorizing the initial investment in the NCI-designated Cancer Centers Program. 
When I first proposed targeting PCNA (proliferating cell nuclear antigen) as a therapeutic approach, the response I got was: “No one will ever make a drug against PCNA. It’s undruggable.” The protein lacks enzymatic activity, has a disordered region, and binds to over 200 other proteins within the cell. From a traditional drug development perspective, these characteristics made PCNA an impossible target.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login